| Literature DB >> 30334369 |
Mohammad Hossein Soltani1, Mohsen Jamshir2, Sepideh Taghavi2, Reza Golpira2, Mohsen Nasiri2, Ahmad Amin2, Nargeuss Abbaszade Marzbali2, Nasim Naderi2.
Abstract
AIMS: Echocardiography is known as the most useful diagnostic test in the assessment of patients with heart failure (HF), and the prognostic significance of echocardiographic findings in HF is well known. In this report, we aim to present the prognostic significance of a limited set of echocardiographic parameters obtained within 24 h of admission of patients enrolled in the Rajaie Acute Systolic Heart Failure registry. METHODS ANDEntities:
Keywords: Acute heart failure; Echocardiography
Mesh:
Substances:
Year: 2018 PMID: 30334369 PMCID: PMC6300822 DOI: 10.1002/ehf2.12358
Source DB: PubMed Journal: ESC Heart Fail ISSN: 2055-5822
A list of definitions for various echocardiographic parameters
| Echocardiographic data | Comment |
|---|---|
| LVEF | Visual estimation or by plane |
| More‐than‐moderate LV enlargement | ≥35 mm/m2 |
| Severe RV enlargement | Basal RV dimension ≥ 39 mm |
| Severe LV diastolic dysfunction in sinus rhythm |
E/A velocity ratio ≥ 2 |
| Significant RV dysfunction |
Basal RV S′ velocity < 10 cm/s |
| More‐than‐moderate MR |
Jet area/LA area ≥ 20% |
| More‐than‐moderate TR |
Jet area in central jets > 5 cm2
|
| More‐than‐moderate AR |
Central jet height/LVOT diameter ≥ 50% |
| More‐than‐moderate MS | MVA < 1.5 cm2 |
| More‐than‐moderate AS |
Aortic jet velocity > 3 m/s |
| Items to be measured | TAPSE, RV S′, IVC size and collapse, TRG, PSAP, LA area |
AR, aortic regurgitation; AS, aortic stenosis; CW, continuous wave Doppler; E, early mitral inflow velocity; E′, mitral annulus tissue velocity; IVC, inferior vena cava; LA, left atrial; LV, left ventricle; LVEF, left ventricular ejection fraction; LVOT, left ventricular outflow tract; MR, mitral regurgitation; MS, mitral stenosis; MVA, mitral valve area; PASP, pulmonary artery systolic pressure; PISA, proximal isovelocity surface area; RA, right atrial; RV, right ventricle; S′, systolic tissue velocity; TAPSE, tricuspid annular plane systolic excursion; TR, tricuspid regurgitation; TRG, tricuspid regurgitation gradient.
Demographic and characteristics of all patients with acute heart failure, n = 230
| Characteristic | Total |
|---|---|
| Age, years, mean (SD) | 52 ± 16 |
| Gender, number (%) | |
| Female | 42 (18) |
| Male | 188 (82) |
| Aetiology, number (%) | |
| Ischaemic cardiomyopathy | 128 (55.7) |
| Non‐ischaemic cardiomyopathy | 102 (44.3) |
| Diabetes, number (%) | 77 (34) |
| Hypertension, number (%) | 55 (24) |
| Smoking, number (%) | 75 (33) |
| Previous MI, number (%) | 52 (23) |
| Severe peripheral oedema, number (%) | 128 (55) |
| Ascites, number (%) | 59 (26) |
| Systolic BP, mm/Hg (mean, SD) | 110 ± 20 |
| Heart rate, b.p.m. (mean, SD) | 87 ± 20 |
| Atrial fibrillation rhythm, number (%) | 48 (21) |
| WRF, number (%) | 67 (29.1) |
| Daily dose (mg) of IV furosemide during admission (mean, SD) | 158 ± 55 |
| Inotrope use during admission, number (%) | 51 (22.1) |
| Length of hospital stay, days (median, IQR) | 9.5 (6–15) |
| In‐hospital death, number (%) | 22 (9.6) |
| Death during 3 months after discharge, number (%) | 34 (16.4) |
BP, blood pressure; IV, intravenous; MI, myocardial infarction; SD, standard deviation; WRF, worsening renal function.
Echocardiographic data of patients with acute heart failure, n = 230
| Echocardiographic data | Value |
|---|---|
| LVEF, %, median (IQR) | 20 (15–23) |
| More‐than‐moderate LV enlargement, number (%) | 145 (63) |
| Severe RV enlargement, number (%) | 53 (23) |
| Severe LV diastolic dysfunction, number (%) | 136 (59.1) |
| Significant RV dysfunction, number (%) | 125 (54.3) |
| More‐than‐moderate MR, number (%) | 132 (57.5) |
| More‐than‐moderate TR, number (%) | 104 (45.1) |
| More‐than‐moderate AI, number (%) | 35 (15.2) |
| More‐than‐moderate MS, number (%) | 4 (1.8) |
| More‐than‐moderate AS, number (%) | 4 (1.8) |
| TRG, mmHg, mean (SD) | 46.7 (14) |
| Estimated PASP, mmHg, mean (SD) | 53.2 (25.1) |
| TAPSE, mm, mean (SD) | 15.1 (3.6) |
| RV S′, cm/s mean (SD) | 9.3 (2.6) |
| IVC size, cm, median (IQR) | 1.9 (1.7–2.2) |
| <50% IVC collapse, number (%) | 117 (51) |
| Left atrial area, cm2, mean (SD) | 30 (8) |
| RV–pulmonary artery coupling, mm/mmHg, median (IQR) | 0.29 (0.21–0.41) |
AI, aortic insufficiency; AS, aortic stenosis; IQR, inter‐quartile range; IVC, inferior vena cava; LV, left ventricle; LVEF, left ventricular ejection fraction; MR, mitral regurgitation; MS, mitral stenosis; PASP, pulmonary artery systolic pressure; RV, right ventricle; SD, standard deviation; TAPSE, tricuspid annular plane systolic excursion; TR, tricuspid regurgitation; TRG, tricuspid regurgitation gradient.
Predictors of worsening renal function (n = 230)
| Variable | Univariate model | Multivariate model | ||||||
|---|---|---|---|---|---|---|---|---|
|
| Wald |
| OR (95% CI) |
| Wald |
| OR (95% CI) | |
| Age | 0.020 | 4.955 | 0.02 | 1.021 (1.002–1.04) | ||||
| AF rhythm | 1.030 | 3.905 | 0.04 | 2.802 (1.008–7.8) | ||||
| Ascites | 1.012 | 11.99 | 0.001 | 3.01 (1.6–5.6) | 0.8 | 4.786 | 0.02 | 2.4 (1.1–5.2) |
| Severe peripheral oedema | 0.214 | 4.28 | 0.03 | 1.24 (1.01–1.5) | ||||
| Baseline creatinine level > 1.5 mg/dL | 0.796 | 11.23 | 0.001 | 2.21 (1.39–3.5) | 0.9 | 4.42 | 0.03 | 2.5 (1.06–6.1) |
| IVC size | 0.153 | 2.35 | 0.03 | 1.1 (0.9–1.4) | ||||
| Significant RV dysfunction | 0.26 | 4.9 | 0.02 | 1.3 (1.03–1.6) | 0.8 | 6.07 | 0.01 | 2.4 (1.2–4.9) |
| More‐than‐moderate TR | 0.09 | 0.08 | 0.7 | 0.9 (0.5–1.7) | ||||
| Severe diastolic dysfunction | 0.382 | 2.809 | 0.094 | 1.465 (0.937–2.290) | ||||
| More‐than‐moderate MR | 0.063 | 0.037 | 0.847 | 1.065 (0.560–2.028) | ||||
| Left atrial enlargement | 0.041 | 0.004 | 0.952 | 0.960 (0.255–3.61) | ||||
| RV–pulmonary circulation coupling | 3.7 | 16.1 | <0.001 | 0.02 (0.004–0.14) | ||||
AF, atrial fibrillation; IVC, inferior vena cava; MR, mitral regurgitation; OR, odds ratio; RV, right ventricle; TR, tricuspid regurgitation.
C statistic for this model is 0.71.
Predictors of in‐hospital mortality
| Variable | Univariate model | Multivariate model | ||||||
|---|---|---|---|---|---|---|---|---|
|
| Wald |
| HR (95% CI) |
| Wald |
| HR (95% CI) | |
| SBP | 0.031 | 6.341 | 0.01 | 0.969 (0.946–0.993) | 0.04 | 6.4 | 0.01 | 0.9 (0.9–1.1) |
| Ascites | 1.6 | 12.8 | <0.0001 | 4.9 (2.05–11.9) | ||||
| WRF | 1.8 | 15.2 | <0.0001 | 6.07 (2.4–15.03) | 2.9 | 20 | <0.0001 | 19.1 (5.2–69.7) |
| LVEF | 0.01 | 0.11 | 0.7 | 0.9 (0.9–1) | ||||
| IVC size | 0.05 | 0.12 | 0.7 | 0.9 (0.6–1.3) | ||||
| Significant RV dysfunction | 0.3 | 3.24 | 0.04 | 1.3 (0.97–1.8) | 0.6 | 3.6 | 0.04 | 1.5 (0.5–4.6) |
| More‐than‐moderate TR | 0.6 | 4.6 | 0.03 | 1.8 (1.05–3.16) | ||||
| Severe diastolic dysfunction | 0.5 | 1.9 | 0.04 | 1.6 (0.8–3.1) | ||||
| More‐than‐moderate MR | 0.3 | 0.64 | 0.4 | 1.4 (0.6–3.5) | ||||
| Left atrial enlargement | 0.8 | 0.475 | 0.5 | 2.1 (0.24–19) | ||||
| RV–pulmonary circulation coupling | 2.6 | 6.1 | 0.04 | 0.07 (0.006–0.89) | ||||
HR, hazard ratio; IVC, inferior vena cava; LVEF, left ventricular ejection fraction; MR, mitral regurgitation; RV, right ventricle; SBP, systolic blood pressure; TR, tricuspid regurgitation; WRF, worsening renal function.
C statistic for this model is 0.87.
C statistics measure for comparing the model using clinical and laboratory factors and the new model by adding significant right ventricular dysfunction
| Model/predictor |
|
|---|---|
| Outcome: worsening renal failure | |
| Model 1 | 0.63 (0.54–0.72) |
| Ascites, baseline creatinine level > 1.5 mg/dL | |
| Model 2 | 0.71 (0.63–0.79) |
| Ascites, baseline creatinine level > 1.5 mg/dL, significant RV dysfunction | |
| Outcome: mortality | |
| Model 1 | 0.86 (0.78–0.94) |
| Systolic blood pressure, worsening renal failure | |
| Model 2 | 0.87 (0.81–0.93) |
| Systolic blood pressure, worsening renal failure, significant RV dysfunction |
RV, right ventricular.
Comparison of the predictors of worsening renal function in the present study and previous investigations
| First author of study and year of publication | Design study, population | Number of patients | Predictor of WRF in univariate analysis | Predictor of WRF in multivariate analysis |
|---|---|---|---|---|
| Verdiani, | Cohort, AHF | 394 |
Prior renal failure |
Age > 75 years |
| Kawase, | Retrospective cohort, AHF | 205 |
Increase in creatinine ≥ 0.3 mg/dL |
Occurrence of hypotension < 90 mmHg within 12 h |
| Raichlin, | Cohort, AHF | 99 |
Aldosterone antagonist treatment |
Aldosterone antagonist treatment |
| Belziti, | Retrospective cohort, AHF | 200 |
Age |
Older than 80 years |
| Maeder, | Sub‐study RCT, AHF | 566 |
Renal failure |
History of renal failure |
| Damman, | Meta‐analysis, AHF | 49 890 |
Baseline GFR |
Baseline chronic kidney disease |
| Sani, | Registry, AHF | 1006 |
Rales |
Rales |
| Cowie, | Cohort, AHF | 299 |
Atrial fibrillation |
Serum creatinine on admission |
| Tandon, | Cohort (acute RVMI) | 48 |
History of diabetes mellitus |
History of diabetes mellitus |
| Soltani, present study | Registry | 230 |
Age |
Ascites |
ACE‐I, angiotensin‐converting enzyme inhibitor; AHF, acute heart failure; ARB, angiotensin receptor blocker; BUN, blood urea nitrogen; GFR, glomerular filtration rate; IHD, ischaemic heart disease; INR, international normalized ratio; LV, left ventricle; LVEF, left ventricular ejection fraction; NT‐pro‐BNP, N‐terminal pro‐BNP; NYHA, New York Heart Association; PASP, pulmonary artery systolic pressure; RCT, randomized controlled trial; RV, right ventricular; RVFAC, RV fractional area change; RVMI, RV myocardial infarction; SBP, systolic blood pressure; TAPSE, tricuspid annular plane systolic excursion; WRF, worsening renal function.